🔍
Search Results - fibrosis+disorders
3
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Treatment of fibrosis-associated pathologies through downstream TGF-β pathway inhibition
Value PropositionInhibits downstream signaling pathway of TGF-β signaling, reducing pleiotropic and off-target effects.Selectively targets tissue specific calpains, increasing efficacy as compared to current TGF-β signaling pathway inhibitory methods.Applicable to several disease models with specific focus on epithelial-to-mesenchymal transition pathologies....
Published: 3/13/2025
|
Inventor(s):
David Kim
,
Harry Dietz
Keywords(s):
Biomarker
,
Cancers
,
Clinical Diagnostics
,
Disease Indication
,
Fibrosis Disorders
,
In Vitro Diagnostics
,
Mechanism-of-action Biomarker
,
Therapeutic Matter
,
Therapeutics
Category(s):
Clinical and Disease Specializations
,
Clinical and Disease Specializations > Fibrosis
,
Clinical and Disease Specializations > Oncology
,
Technology Classifications > Diagnostics > Biomarkers
,
Technology Classifications > Therapeutic Modalities > Targets
,
Technology Classifications > Diagnostics > In Vitro Diagnostics
,
Technology Classifications > Diagnostics
,
Technology Classifications > Therapeutic Modalities
Methods and Applications of a Global Assay of Coagulation and Fibrinolysis
Unmet NeedExcessive blood clotting, or thrombotic disorders are a life threatening condition that can cause heart attacks, strokes, organ damage and death. Importantly, those who develop venous thromboembolism (VTE) are at a high risk of recurrence, with a third of patients having a recurrence in 10 years. However, VTEs are often preventable with strategies...
Published: 3/13/2025
|
Inventor(s):
Neil Goldenberg
Keywords(s):
Assay
,
Blood Disorder
,
Clinical Diagnostics
,
Disease Indication
,
Fibrosis Disorders
,
In Vitro Diagnostics
Category(s):
Technology Classifications > Diagnostics > In Vitro Diagnostics
,
Clinical and Disease Specializations
,
Technology Classifications > Research Tools > Assays
Targeted Epigenetic Therapy against Distal Regulatory Element of TGFB2 Expression for Scleroderma and Fibrotic Disease
Unmet NeedScleroderma disorders comprise a heterogeneous group of conditions linked by the presence of thickened, sclerotic skin lesions. These conditions result in a poor quality of life and have a poor prognostic outcome. In particular, systemic sclerosis (SSc) has a 10 year mortality rate of approximately 30%. However, the pathogenic mechanisms of...
Published: 3/13/2025
|
Inventor(s):
Harry Dietz
,
Joseph Shin
Keywords(s):
Biomarker
,
Clinical Diagnostics
,
Diagnostic Biomarker
,
Disease Indication
,
Fibrosis Disorders
,
In Vitro Diagnostics
,
Prognostic Biomarker
,
Therapeutics
Category(s):
Clinical and Disease Specializations
,
Clinical and Disease Specializations > Fibrosis
,
Technology Classifications > Diagnostics > Biomarkers
,
Technology Classifications > Diagnostics > Diagnostic Biomarkers
,
Technology Classifications > Diagnostics > In Vitro Diagnostics
,
Technology Classifications > Diagnostics > Prognostics Biomarkers
,
Technology Classifications > Therapeutic Modalities
,
Technology Classifications > Diagnostics
JHTV Home
|
Search
|
Login/Subscribe
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by
Inteum